CSF3 and neutropenia: In patients who have experienced a prior episode of FN or dose-limiting neutropenia [48], the use of secondary prophylaxis with G-CSF can be considered individually if the dose reductions or delay of antineoplastic treatments can negatively affect prognosis [I, A] [2, 11, 45, 46].